People with schizophrenia die 15-20 years earlier than the general population, and cardiovascular disease is a leading cause. Autonomic dysfunction may be the link.
The Evidence
A 2025 umbrella review published in Translational Psychiatry found large reductions in parasympathetic HRV markers in schizophrenia:
HF power: Effect size = -0.97 (p = 2.33 × 10⁻⁶) — large effect, 1,353 patients vs 1,702 controls
RMSSD: Effect size = -0.93 (p = 3.12 × 10⁻⁶) — large effect, 1,016 patients vs 1,469 controls
These effect sizes are larger than depression (-0.53 to -0.60) or anxiety (-0.45), though smaller than PTSD (-1.96).
Evidence quality was rated "Suggestive" (Class III) — the second-highest credibility tier.
Half of Patients Have Autonomic Dysfunction
A 2025 cluster analysis study found approximately 50% of acute schizophrenia patients have significant cardiac autonomic dysfunction (CADF).
The severity correlated with:
- Age
- Body mass index (BMI)
- Disease duration
- Symptom severity
This isn't just a medication side effect — the disease itself damages autonomic function.
The Medication Problem
Antipsychotics significantly worsen HRV. A 2024 study of 164 patients found:
Worst for HRV:
- Clozapine combination therapy
- Clozapine monotherapy
- Olanzapine
Better preserved HRV:
- Ziprasidone
- Risperidone
- Aripiprazole
The clinical dilemma: Clozapine is the most effective treatment for treatment-resistant schizophrenia, but has the worst cardiac autonomic effects.
HRV May Be a Familial Marker
Intriguingly, healthy first-degree relatives of schizophrenia patients also show HRV abnormalities similar to prodromal (early warning) stages. This suggests HRV may be a potential endophenotype — a heritable marker associated with the condition.
Why This Matters
The research points to multiple mechanisms:
Reduced vagal tone — decreased HF power and RMSSD indicate parasympathetic withdrawal
Sympathetic dominance — elevated LF/HF ratio compared to controls
Medication compounding — antipsychotics add to baseline dysfunction
The 2025 umbrella review noted that "no two diseases exhibited identical altered HRV patterns," suggesting HRV profiles may help differentiate between psychiatric conditions.
Practical Implications
For clinicians: Monitor HRV and cardiac function, especially on clozapine. Consider aripiprazole or risperidone if cardiovascular risk is high.
For patients/families: Address modifiable factors — smoking, sedentary behavior, and metabolic syndrome all compound the autonomic deficit.
For monitoring: HRV may serve as a state marker tracking symptom severity and treatment response.
Important Caveat
High heterogeneity across studies (I² = 94-95%) means results vary considerably. Patients fall into distinct subgroups with different autonomic profiles. "Schizophrenia" likely represents multiple underlying conditions with different autonomic signatures.
The Bottom Line
Schizophrenia significantly reduces HRV with large effect sizes (-0.93 to -0.97). About half of acute patients have cardiac autonomic dysfunction. Medications — particularly clozapine and olanzapine — compound the problem, while aripiprazole preserves HRV better. This autonomic dysfunction may explain part of the 15-20 year life expectancy gap seen in schizophrenia.
Sources
[4] Altered Heart Rate Variability in Schizophrenia: A State Marker. PMC. accessibility.link.new-tab